Drug
Adrecizumab
Adrecizumab is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Other(1)
Detailed Status
Completed4
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
unknown120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
NCT03085758
completedphase_2
Adrecizumab in Cardiogenic Shock
NCT03989531
unknownphase_2
Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)
NCT04252937
completedphase_1
Adrecizumab-LPS Study
NCT03083171
completedphase_1
Adrecizumab Phase 1 Trial
NCT02991508
Clinical Trials (5)
Showing 5 of 5 trials
NCT03085758Phase 2
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
NCT03989531Phase 2
Adrecizumab in Cardiogenic Shock
NCT04252937Phase 2
Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)
NCT03083171Phase 1
Adrecizumab-LPS Study
NCT02991508Phase 1
Adrecizumab Phase 1 Trial
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5